Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NSD3 Double Nickase Plasmid (h): sc-402721-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NSD3 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- NSD3 Double Nickase Plasmid (h) and NSD3 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting NSD3. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NSD3 Antibody (E-3): sc-398186
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NSD3 Double Nickase Plasmid (h) | sc-402721-NIC | 20 µg | $410.00 | |||
NSD3 Double Nickase Plasmid (h2) | sc-402721-NIC-2 | 20 µg | $410.00 |
NSD3 (WHSC1L1) encodes a SET domain–containing histone lysine methyltransferase that regulates chromatin accessibility and transcriptional output through methylation of histone H3 and coordination of epigenetic reader/writer complexes. By shaping enhancer and promoter states, NSD3 influences core programs controlling cell-cycle progression, differentiation, and DNA damage responses, and it interfaces with broader chromatin remodeling and transcriptional elongation processes. Altered NSD3 activity or dosage has been linked to dysregulated gene expression in oncogenic contexts, including tumors where 8p11 amplification and epigenetic reprogramming are prominent, making it a useful node for studying chromatin-driven disease mechanisms.
NSD3 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the NSD3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within NSD3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt NSD3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of NSD3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.